Corbus Pharmaceuticals Holdings, Inc.
General ticker "CRBP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $122.8M (TTM average)
Corbus Pharmaceuticals Holdings, Inc. follows the US Stock Market performance with the rate: 39.4%.
Estimated limits based on current volatility of 2.5%: low 10.11$, high 10.85$
Factors to consider:
- Total employees count: 33 as of 2022
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Operational and conduct risks, Significant losses, Substantial financing needs, Third-party risks, Geopolitical risks
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [4.61$, 19.54$]
- 2025-12-31 to 2026-12-31 estimated range: [2.18$, 9.09$]
Financial Metrics affecting the CRBP estimates:
- Negative: with PPE of -3.5 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -29.78 <= 0.33
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Interest expense per share per price, % of 1.33 <= 3.41
Short-term CRBP quotes
Long-term CRBP plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $39.84MM | $45.08MM | $48.72MM |
| Operating Income | $-39.84MM | $-45.08MM | $-48.72MM |
| Non-Operating Income | $-2.51MM | $0.47MM | $8.51MM |
| Interest Expense | $2.13MM | $3.86MM | $1.87MM |
| R&D Expense | $16.14MM | $31.17MM | $32.22MM |
| Income(Loss) | $-42.35MM | $-44.60MM | $-40.21MM |
| Profit(Loss)* | $-55.83MM | $-44.60MM | $-40.21MM |
| Stockholders Equity | $32.99MM | $-6.91MM | $142.43MM |
| Assets | $66.31MM | $28.27MM | $155.88MM |
| Operating Cash Flow | $-37.54MM | $-36.10MM | $-41.79MM |
| Capital expenditure | $0.01MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $30.07MM | $35.64MM | $-121.31MM |
| Financing Cash Flow | $-0.53MM | $-2.82MM | $166.58MM |
| Earnings Per Share** | $-13.39 | $-10.31 | $-3.68 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.